GMAB
Genmab A/S
NASDAQ · Healthcare · Biotechnology · DK
$33.60
−2.35%Institutional positioning
13F filings over the trailing two quarters
New 91Increased 210Reduced 199Sold out 30
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | Increased | 13,133,131 | Aug 14, 2026 |
| ORBIS ALLAN GRAY LTD | Reduced | 12,925,578 | May 15, 2026 |
| Orbis Allan Gray Ltd | Reduced | 11,368,161 | Aug 14, 2026 |
| ALLIANCEBERNSTEIN L.P. | Reduced | 9,557,149 | May 15, 2026 |
| Deep Track Capital, LP | Increased | 8,650,000 | Aug 14, 2026 |
| ALLIANCEBERNSTEIN L.P. | Reduced | 8,644,877 | Aug 14, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 7,967,836 | May 15, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | Increased | 6,865,000 | Aug 14, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | Unchanged | 4,975,324 | Aug 13, 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | Reduced | 4,975,324 | May 14, 2026 |
| BlackRock, Inc. | Increased | 4,671,252 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 4,536,565 | May 13, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 4,414,550 | May 14, 2026 |
| Sofinnova Investments, Inc. | Increased | 4,045,215 | Aug 14, 2026 |
| DEEP TRACK CAPITAL, LP | New Position | 3,663,250 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings